Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Ulipristal acetate (Fibristal -- Allergan Inc.) indication: uterine fibroids

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be reimbursed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery, and the intermittent treatment of moderate to severe signs...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health November 2017, 2017
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Canada
Norpregnadienes / Therapeutic Use
Cost-benefit Analysis
Leiomyoma / Drug Therapy
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02083nam a2200325 u 4500
001 EB002001066
003 EBX01000000000000001163967
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee recommendation: Ulipristal acetate (Fibristal -- Allergan Inc.)  |h Elektronische Ressource  |b indication: uterine fibroids 
246 3 1 |a Drug reimbursement recommendation ulipristal acetate (Fibristal) 
246 3 1 |a Ulipristal acetate (Fibristal -- Allergan Inc.) 
250 |a Version 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c November 2017, 2017 
300 |a 1 PDF file (8 pages) 
653 |a Insurance, Health, Reimbursement 
653 |a Canada 
653 |a Norpregnadienes / therapeutic use 
653 |a Cost-Benefit Analysis 
653 |a Leiomyoma / drug therapy 
710 2 |a CADTH Canadian Drug Expert Committee 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
500 |a "Final.". - "This recommendation supersedes the CADTH Canadian Drug Expert Committee (CDEC) recommendation for this drug and indication dated November 15, 2013." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK540533  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be reimbursed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery, and the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, with the duration of each treatment course being three months, if the following conditions are met: Conditions: The patient is under the care of an obstetrician/gynecologist. Treatment should be limited to a maximum of four courses of therapy 

Similar Items